Autres langues BioCryst Pharmaceuticals, Inc.

Actions

BCRX

US09058V1035

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 12/08/2026			Varia. 5j.	Varia. 1 janv.
10,59 ^USD	+2,42%		+16,76%	+35,77%

06/08	BioCryst Pharmaceuticals, Inc. : RBC Capital Markets reste à l'achat	ZM
05/08	BioCryst Pharmaceuticals, Inc. : Wedbush reste à l'achat	ZM

Autres langues

05/08	BioCryst Pharmaceuticals, Inc. Updates Earnings Guidance for the Full Year 2026
05/08	BioCryst Pharmaceuticals Q2 Earnings, Revenue Increase; 2026 Revenue Outlook Raised
05/08	BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
05/08	Earnings Flash (BCRX) BioCryst Pharmaceuticals Posts Q2 EPS $0.30, vs. FactSet Est of $0.15
05/08	Earnings Flash (BCRX) BioCryst Pharmaceuticals, Inc. Reports Q2 Revenue $218.2M, vs. FactSet Est of $183.3M
05/08	BioCryst: Q2 Earnings Snapshot
05/08	BioCryst Reports Second Quarter 2026 Financial Results
22/07	BioCryst to Report Second Quarter 2026 Financial Results on August 5
15/07	BioCryst Pharmaceuticals, Inc. Announces Appointment of David W. Jenkins as Chief Scientific Officer, Effective July 15, 2026
15/07	BioCryst Appoints David W. Jenkins as Chief Scientific Officer
02/07	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29/06	BioCryst scraps internal drug discovery programs, leans on partnerships to cut costs
29/06	BioCryst to Discontinue Internal Discovery Programs, Close Birmingham Facility by Year-End
29/06	BioCryst Pharmaceuticals, Inc. Discontinues Internal Discovery Programs And Closes Birmingham Research Facility
29/06	BioCryst Pharmaceuticals, Inc.(NasdaqGS:BCRX) dropped from Russell 2000 Value Benchmark
29/06	BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility
29/06	BioCryst Pharmaceuticals, Inc.(NasdaqGS:BCRX) dropped from Russell 3000E Value Benchmark
29/06	BioCryst Pharmaceuticals, Inc.(NasdaqGS:BCRX) dropped from Russell 3000 Value Benchmark
29/06	BioCryst Pharmaceuticals, Inc.(NasdaqGS:BCRX) dropped from Russell Small Cap Comp Value Benchmark
29/06	BioCryst Pharmaceuticals, Inc.(NasdaqGS:BCRX) dropped from Russell 2500 Value Benchmark
12/06	BioCryst Pharmaceuticals' New Clinical Data Demonstrated Reduced Hereditary Angioedema Attacks With Orladeyo Treatment
12/06	BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
12/06	BioCryst Pharmaceuticals Presents New Clinical Data and Real-World Evidence for HAE Portfolio at the European Academy of Allergy and Clinical Immunology Annual Meeting
09/06	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
27/05	BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting